About
- - Company
    - About Sensus Healthcare
    - Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive, and cost-effective treatments for both oncological and non-oncological conditions.
      
      Read More
  - Patient Advocates
  - FAQ
    - - What is SRT?
        We offer a painless, safe and highly effective non-surgical skin cancer treatment that is an alternative to surgery—Superficial Radiation Therapy using the SRT-100™.
        
        Go to FAQ
      - What does SRT treat?
        The SRT-100™ is an excellent treatment option for patients with the following conditions: Keloid scars, Basal cell carcinoma, Squamous cell carcinoma, Metatypical carcinoma, Cutaneous appendage carcinoma, Actinic keratosis, Kaposi’s sarcoma.
        
        Go to FAQ
      - Is SRT right for me?
        The SRT-100™ doesn’t harm surrounding or underlying healthy tissue while targeting cancer cells. The SRT-100™ provides excellent cosmetic outcomes and is a great alternative for patients with various co-morbidities.
        
        Go to FAQ
      - What should I expect?
        You should expect the same results as surgery, but with these additional benefits: No pain, No anesthesia, No cutting, No bleeding, No stitching, No scarring, No interruption of lifestyle, No reconstructive surgery
        
        Go to FAQ
      - Is the SRT-100 safe?
        The SRT-100™ is a safe and proven technology that effectively treats non-melanoma skin cancers, keloid scarring, actinic keratosis and Kaposi’s sarcoma. It is utilized by dermatologists and radiation oncologists all over the world because it delivers good patient outcomes.
        
        Go to FAQ
  - Careers
    - - Sensus - Field Service Engineer
    - View Career Opportunities
Physicians
Patients
Investors
- Corporate Governance Guidelines
- Code of Ethics and Business Conduct
Resources
Contact Us

Report on Hyaluronic Acid & Oligopeptides cocktail treatments through Dermoelectroporation

Dr. James Fulton, vivant Skin Care , Miami Florida, USA

Preliminary Study

To evaluate the safety, tolerability and effectiveness of transdermal delivery of a Hyaluronic Acid & Oligopeptides cocktail
for either facial lifting and finelines reduction purposes through Dermoelectroporation®.

Study Design

Delivered every 1 or 2 weeks for a total of 8
treatments.
Oligopeptides with Hyaluronic acid gel (Vivant Skin
Care) was delivered
Ultrapeel® Transderm® Ionto Meso System
Repeat ideally every 12 week

Materials and Methods

Materials

Oligopeptides serum 10% Reduces Lines & Generates New Collagen
Hyaluronic acid serum 1% Fills out the Dermis and Hydrates the Joints
Ultrapeel® Transderm Ionto Meso® system from Mattioli Engineering

Methods

Transdermal delivery of the cocktail through Dermoelectroporation® technology:
2 Steps Prodecure:
- a) Microdermabrasion
- b) Transdermal delivery of:
  Prepare solution using a 10cc syringe. Use 5cc’s per side of the face, concentrating on problematic areas like the cheeks and forehead at lateral brow line.
  Per 10cc syringe
  5cc Oligopeptides
Application of proper follow up at the end.

Results & Conclusions

Patients were treated with the following results: Patients drastically reduced inches in weeks.
Transdermal delivery is possible and safe with no contraindications reported.
all patients showed a good level of improvement and she was so happy with results.

Report on Hyaluronic Acid and oligopeptides cocktail treatment through Dermoelectroporation Pn. 55100200/E Mattioli Engineering All rights

Start your journey to a happy & healthy recovery.